載入中
Vir Biotechnology, Inc. operates as an immunology company with commercialized products, dedicated to devising therapeutic solutions for the treatment and prevention of significant infectious diseases. Its pipeline features several key candidates: Sotrovimab (branded as Xevudy, or VIR-7832), a neutralizing monoclonal antibody for both treating and preventing SARS-CoV-2 infection; VIR-2218 and VIR-3434, aimed at hepatitis B virus; VIR-2482, targeting the prevention of influenza A virus; and VIR-1111, designed to prevent human immunodeficiency virus. The firm maintains a robust network of strategic partnerships and collaborations. These include grant support from organizations like the Bill & Melinda Gates Foundation and the National Institutes of Health. It holds option and licensing arrangements with entities such as Brii Biosciences Limited, and a collaboration and license agreement with Alnylam Pharmaceuticals, Inc. Further licensing relationships exist with The Rockefeller University and MedImmune, Inc. Collaborations extend to WuXi Biologics and Glaxo Wellcome UK Ltd., alongside a research agreement with GlaxoSmithKline Biologicals SA. Furthermore, Vir has secured a manufacturing contract with Samsung Biologics Co.,Ltd. for SARS-CoV-2 antibodies and a clinical development partnership with Gilead Sciences, Inc. focused on chronic hepatitis B virus. The company, established in 2016, is headquartered in San Francisco, California.
收盤時
US$11.30
−US$0.40 · -3.42%
盤後
US$11.20
−US$0.10 · -0.88%
10月12日 下午5:28 ET
盤中時間採用ET。市場資料可能有所延遲。
Vir Biotechnology, Inc. operates as an immunology company with commercialized products, dedicated to devising therapeutic solutions for the treatment and prevention of significant infectious diseases. Its pipeline features several key candidates: Sotrovimab (branded as Xevudy, or VIR-7832), a neutralizing monoclonal antibody for both treating and preventing SARS-CoV-2 infection; VIR-2218 and VIR-3434, aimed at hepatitis B virus; VIR-2482, targeting the prevention of influenza A virus; and VIR-1111, designed to prevent human immunodeficiency virus. The firm maintains a robust network of strategic partnerships and collaborations. These include grant support from organizations like the Bill & Melinda Gates Foundation and the National Institutes of Health. It holds option and licensing arrangements with entities such as Brii Biosciences Limited, and a collaboration and license agreement with Alnylam Pharmaceuticals, Inc. Further licensing relationships exist with The Rockefeller University and MedImmune, Inc. Collaborations extend to WuXi Biologics and Glaxo Wellcome UK Ltd., alongside a research agreement with GlaxoSmithKline Biologicals SA. Furthermore, Vir has secured a manufacturing contract with Samsung Biologics Co.,Ltd. for SARS-CoV-2 antibodies and a clinical development partnership with Gilead Sciences, Inc. focused on chronic hepatitis B virus. The company, established in 2016, is headquartered in San Francisco, California.
日內區間
目前US$11.30
52週區間
目前US$11.30
盤中時間採用ET。市場資料可能有所延遲。
Vir Biotechnology, Inc. operates as an immunology company with commercialized products, dedicated to devising therapeutic solutions for the treatment and prevention of significant infectious diseases. Its pipeline features several key candidates: Sotrovimab (branded as Xevudy, or VIR-7832), a neutralizing monoclonal antibody for both treating and preventing SARS-CoV-2 infection; VIR-2218 and VIR-3434, aimed at hepatitis B virus; VIR-2482, targeting the prevention of influenza A virus; and VIR-1111, designed to prevent human immunodeficiency virus. The firm maintains a robust network of strategic partnerships and collaborations. These include grant support from organizations like the Bill & Melinda Gates Foundation and the National Institutes of Health. It holds option and licensing arrangements with entities such as Brii Biosciences Limited, and a collaboration and license agreement with Alnylam Pharmaceuticals, Inc. Further licensing relationships exist with The Rockefeller University and MedImmune, Inc. Collaborations extend to WuXi Biologics and Glaxo Wellcome UK Ltd., alongside a research agreement with GlaxoSmithKline Biologicals SA. Furthermore, Vir has secured a manufacturing contract with Samsung Biologics Co.,Ltd. for SARS-CoV-2 antibodies and a clinical development partnership with Gilead Sciences, Inc. focused on chronic hepatitis B virus. The company, established in 2016, is headquartered in San Francisco, California.
日內區間
目前US$11.30
52週區間
目前US$11.30
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 6855.6萬 USD | 7420.5萬 USD | 8618萬 USD | 16.16億 USD | 10.95億 USD |
| 銷貨成本 | 1170.6萬 USD | 1540.4萬 USD | 2221.6萬 USD | 1.62億 USD | 7167.6萬 USD |
| 毛利 | 5685萬 USD | 5880.1萬 USD | 6396.4萬 USD | 14.54億 USD | 10.24億 USD |
| 研究與開發 | 4.33億 USD | 4.63億 USD | 5.51億 USD | 4.68億 USD | 4.42億 USD |
| 銷售、一般及管理費用 | 9207.4萬 USD | 1.19億 USD | 1.74億 USD | 1.53億 USD | 1.61億 USD |
| 營業費用 | 5.25億 USD | 5.82億 USD | 7.25億 USD | 6.21億 USD | 6.03億 USD |
| 利息收入 | 4023.8萬 USD | 7180.9萬 USD | 8699萬 USD | 2809.2萬 USD | 43.9萬 USD |
| 折舊和攤銷 | 1168萬 USD | 1455.9萬 USD | 1945.1萬 USD | 1549.2萬 USD | 1198.3萬 USD |
| 營業利益 | −4.68億 USD | −5.23億 USD | −6.61億 USD | 8.33億 USD | 4.21億 USD |
| 淨利 | −4.38億 USD | −5.22億 USD | −6.15億 USD | 5.16億 USD | 5.29億 USD |
公司資料更新於 2026年10月12日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$23.50
上漲空間 107.96%報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI5302.2萬0.00%2.3兆 USD0.03%US$381.57-0.10%
iShares Russell 2000 ETFIWM4168.69萬0.05%787.4億 USD0.19%US$277.9-0.37%
Vanguard Morningstar Small-Cap ETFVB3819.45萬0.02%1853億 USD0.03%US$288.16-0.46%
State Street SPDR S&P Biotech ETFXBI2932.97萬0.30%98.74億 USD0.35%US$151.4-1.54%
Vanguard Morningstar Small-Cap Growth ETFVBK2187.58萬0.05%447億 USD0.05%US$340.88-1.12%
Vanguard Extended Market ETFVXF1547.77萬0.02%954億 USD0.05%US$233.52-0.63%
Dimensional - US Small Cap ETFDFAS1391.99萬0.04%338.69億 USD0.31%US$78.17-0.23%
State Street SPDR Portfolio S&P 600 Small Cap ETFSPSM1361.6萬0.09%158.4億 USD0.03%US$53.42-0.06%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Morningstar Small-Cap ETFVBState Street SPDR S&P Biotech ETFXBIVanguard Morningstar Small-Cap Growth ETFVBKVanguard Extended Market ETFVXFDimensional - US Small Cap ETFDFASState Street SPDR Portfolio S&P 600 Small Cap ETFSPSMAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
